Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

被引：0
|
作者：
Kropff, MH [1 ]
Bisping, G [1 ]
Wenning, D [1 ]
Berdel, WE [1 ]
Kienast, J [1 ]
机构：
[1] Univ Munster, Dept Med Hematol & Oncol, Munster, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4923
引用
收藏
页码：313B / 313B
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [42] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma.
    Popat, Rakesh
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Odeh, Liz
    Foot, Nicola
    Oakervee, Heather
    Cavenagh, James D.
    BLOOD, 2006, 108 (11) : 1011A - 1011A
  • [44] Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma
    Rahbari, Kian J.
    Nosrati, Jason D.
    Spektor, Tanya M.
    Berenson, James R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : E339 - E343
  • [45] Phase I study of bortezomib and 153Sm-Lexidronam combination for refractory and relapsed multiple myeloma.
    Berenson, James R.
    Swift, Regina A.
    Mapes, Russell
    Abaya, Christina D.
    BLOOD, 2006, 108 (11) : 1011A - 1012A
  • [46] Bortezomib is cost-effective for the treatment of relapsed and refractory multiple myeloma.
    Mehta, J
    Duff, S
    Gupta, S
    BLOOD, 2003, 102 (11) : 500A - 501A
  • [47] Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma.
    Yeh, H. S.
    Swift, R. A.
    Ferretti, D.
    Mapes, R. A.
    Goeckeler, W. F.
    Berenson, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [48] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [49] Predictors of response to upfront bortezomib, lenalidomide and dexamethasone (VRd) in multiple myeloma.
    Keruakous, Amany
    Day, Silas
    Borogovac, Azra
    Holter, Jennifer L.
    Asch, Adam Steven
    Yuen, Carrie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Jagannath, Sundar
    Richardson, Paul G.
    Barlogie, Bart
    Berenson, James R.
    Singhal, Seema
    Irwin, David
    Srkalovic, Gordan
    Schenkein, David P.
    Esseltine, Dixie L.
    Anderson, Kenneth C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 929 - 934
12345